title: Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.
authors.forename: James H
authors.initials: JH
authors.lastname: Heller
authors.forename: Gail A
authors.initials: GA
authors.lastname: Spiridigliozzi
authors.forename: P Murali
authors.initials: PM
authors.lastname: Doraiswamy
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Sullivan
authors.forename: Bythe G
authors.initials: BG
authors.lastname: Crissman
authors.forename: Priya S
authors.initials: PS
authors.lastname: Kishnani
mesh_terms: D000293:Adolescent; D002648:Child; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D000077265:Donepezil; D004314:Down Syndrome / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007189:Indans / Q000494:pharmacology*; D007802:Language; D008297:Male; D018697:Nootropic Agents / Q000494:pharmacology; D010865:Pilot Projects; D010880:Piperidines / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome; D014705:Verbal Behavior / Q000187:drug effects* / Q000502:physiology
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil